Frazier Healthcare Partners’ SPAC has found a partner. The longstanding Seattle-based venture firm inked a deal to bring Dutch biotech company NewAmsterdam Pharma public through a merger with its blank check company founded in 2020, Frazier Lifesciences Acquisition Corp (FLAC). New Amsterdam is expected to raise $373 million from the deal, which was sweetened with a $235 million PIPE (private investment in public equity) co-led by Frazier and Bain Capital Life Sciences. Frazier raised $138 million for its SPAC in late 2020. The deal comes as investor sentiment towards SPACs has deteriorated.